In September 2015 - +18 months ago - MSB's Japanese partner, JCR, received full Japanese approval to commericalise JCR's TEMCELL product, which is manufactured under licence from MSB in exchange for royalties, on the sale of TEMCELL, payable to MSB.
Today's Appendix 4-C quarterly cash flow statement will provide some insights into the sort of funding source Japan will be for MSB.
At the time of the approval being granted, several posters were pointing to this as being a material development in terms of cash flow potential and even the company's management - in the Appendic 4-C for the 3-months to December 2016 - made specific reference to royalty income from Japan in the as a contributor to MSB's cash position for the March quarter of 2017.
So I suspect many might be keenly looking at this figure in today's announcement.
(It is a bit surprising that Japan isn't discussed as much lately as it once was, but I suppose there are so many other things going on with MSB...)
Japan as a Funding Source
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
-0.010(0.76%) |
Mkt cap ! $1.495B | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.33 | $1.28 | $1.819M | 1.396M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 29972 | $1.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 2008 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |